HomeInvestingEarningsJNJ Earnings: Broad Innovation & Top Line Performance

JNJ Earnings: Broad Innovation & Top Line Performance

Johnson & Johnson (JNJ) looks undervalued with the market likely but not fully appreciating the broad innovation across the firm’s pipeline, notes Morningstar’s Damien Conover. He and Third Bridge’s Lee Brown discuss JNJ’s earnings. Brown suggests that JNJ’s top line performance was driven by the company innovative medicine segment.

Trading 360

17 Jul 2024

SHARE

ON AIR
9:00 pm
Gamma On
replay
12:00 am
Fast Market
REPLAY
1:00 am
Next Gen Investing
REPLAY
2:00 am
Gamma On
REPLAY
2:30 am
Gamma On
REPLAY
3:00 am
Gamma On
REPLAY
3:30 am
Gamma On
REPLAY
4:30 am
Gamma On
REPLAY
5:00 am
Gamma On
REPLAY
5:30 am
Gamma On
REPLAY
6:00 am
Gamma On
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
7:00 pm
Gamma On
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market Overtime
REPLAY
ON AIR
9:00 pm
Gamma On
REPLAY
education
10:00 pm
Inside the Mind of a Trader
REPLAY
education
10:30 pm
Inside the Mind of a Trader
REPLAY
education
11:00 pm
Inside the Mind of a Trader
REPLAY
education
11:30 pm
Your First Trade
REPLAY

Get the Market Minute

Daily insights for every investor